ArticleInterventional pain medicine2026
FactFinders for patient safety: Hyperglycemia and steroid injections.
Article in Interventional pain medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This series of FactFinders presents a brief summary of the evidence and outlines recommendations regarding hyperglycemia and steroid injections. The evidence in support of the following facts is presented: (1) Corticosteroid injections can safely be administered to patients with Diabetes-Mellitus Type 2 (DM2) in most cases, including those with suboptimal management. Because there is a risk of hyperglycemia and related complications in these patients, a trial of conservative care before proceeding with a steroid injection is optimal. Patients with DM2 should be counseled on the signs, risks, and sequelae of hyperglycemia in the post-injection period and appropriate steps to take if significant hyperglycemia occurs. (2) No universally accepted "safe" pre-injection glucose cutoff exists, but expert consensus and studies provide some guidance, and physicians should engage in shared decision-making with patients to consider individualized thresholds to mitigate potential harms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.